FDA concluded in 2026 that evidence was insufficient to support wound-healing effectiveness
none of the compounds have been studied for continuous use
it is not approved for human or veterinary use, and nothing below describes or recommends any form of administration to people
1 H NMR (300 MHz, DMSO) 8.23 (d, J = 7.4 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.41 (d, J = 6.6 Hz, 9H), 7.23 (s, 1H), 7.12 7.04 (m, 6H), 6.78 (d, J = 5.4 Hz, 1H), 6.67 (d, J = 11.0 Hz, 1H), 4.56 (d, J = 6.6 Hz, 1H), 4.14 (q, J = 7.4 Hz, 1H), 3.60 (s, 3H), 3.51 (d, J = 8.0 Hz, 2H), 2.78 (dq, J = 32.2, 7.5 Hz, 4H), 1.36 (d, J = 2.4 Hz, 24H)
Some of this research reported extended survival and delayed onset of certain age-related changes in treated animal cohorts compared to controls, which is part of why the compound continues to attract laboratory interest today
Cagrilintide 5mg Research Peptide 3